Skip to main
ABBV
ABBV logo

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 36 analyst ratings
Buy
Strong Buy 28%
Buy 42%
Hold 28%
Sell 0%
Strong Sell 3%

Bulls say

AbbVie has reaffirmed a strong long-term sales outlook with guidance indicating a high single-digit compound annual growth rate (CAGR) from 2024 to 2029, backed by anticipated robust sales of Skyrizi and Rinvoq, which are projected to exceed $20 billion and $11 billion, respectively, by 2027. The company's fourth quarter of 2024 delivered sales of $15.1 billion, exceeding expectations primarily due to the success of key products in its immunology portfolio, illustrating its solid market position. Additionally, AbbVie is maintaining its reported EPS guidance for 2025 at $12.12–$12.32, reflecting confidence in financial performance amidst ongoing investments in research and development.

Bears say

AbbVie faces significant downside risks that could adversely affect its stock performance, primarily due to disappointing commercial execution on key assets such as Skyrizi, Rinvoq, and Botox, coupled with potential regulatory setbacks and clinical data failures. The company's reliance on discretionary consumer spending for its aesthetics business introduces vulnerability, especially in light of ongoing macroeconomic challenges that could hinder overall sales growth. Additionally, heightened competitive pressures, particularly with the impending erosion of Humira’s market share due to biosimilar entries and stagnant market penetration with Rinvoq and Skyrizi, further contribute to a negative outlook for AbbVie’s future financial performance.

AbbVie (ABBV) has been analyzed by 36 analysts, with a consensus rating of Buy. 28% of analysts recommend a Strong Buy, 42% recommend Buy, 28% suggest Holding, 0% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 36 analysts, AbbVie (ABBV) has a Buy consensus rating as of Jul 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.